BeStock  
Stocks › GLUE

Monte Rosa Therapeutics GLUE

US equityMarket cap rank #3349
$8.64 −$0.27 (-3.03%)
Market closed · Nov 20, 8:20 pm ET · Last extended-hours $8.64 0.00%
Open$8.73
Prev close$8.91
Day range$8.48 – $9.04
Volume2.52M
Market cap$738.29M
P/E (TTM)–
Dividend yield–

GLUE Stock News

Headlines matching Monte Rosa Therapeutics or the GLUE ticker, most recent first.

  • Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $28 NegativeMarket news · 7 Aug 2026 · Direct mention
  • Analysts Offer Insights on Healthcare Companies: Monte Rosa Therapeutics (GLUE), Mineralys Therapeutics, Inc. (MLYS) and Adagene (ADAG)TipRanks · 13 Aug 2026 · Direct mention
  • J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $27 NegativeMarket news · 11 Aug 2026 · Direct mention
  • Jefferies Initiates Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Announces Target Price $25Market news · 1 Aug 2026 · Direct mention
  • Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $35Market news · 15 Jul 2026 · Direct mention
  • Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $35 PositiveMarket news · 30 Jun 2026 · Direct mention
  • Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $29Market news · 24 Jun 2026 · Direct mention
  • Wedbush Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37Market news · 9 May 2026 · Direct mention
  • J.P. Morgan Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Raises Target Price to $31 PositiveMarket news · 11 May 2026 · Direct mention
  • H.C. Wainwright Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $25Market news · 6 Nov 2026 · Direct mention
  • Guggenheim Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $28Market news · 6 Nov 2026 · Direct mention
  • Wells Fargo Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $25 NegativeMarket news · 6 Nov 2026 · Direct mention
  • Jefferies Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Cuts Target Price to $15 NegativeMarket news · 6 Nov 2026 · Direct mention
  • Piper Sandler Maintains Monte Rosa Therapeutics(GLUE.US) With Buy Rating, Maintains Target Price $37Market news · 10 Nov 2026 · Direct mention
  • Analysts Are Bullish on Top Healthcare Stocks: Monte Rosa Therapeutics (GLUE), Sagimet Biosciences, Inc. Class A (SGMT) PositiveTipRanks · 5 Oct 2026 · Direct mention

Discussion

No comments yet — be the first to weigh in on GLUE.

Sign in to join the discussion.

Scroll to Top